3 assets in Ovarian Serous Surface Papillary Adenocarcinoma

Therapeutic assets addressing Ovarian Serous Surface Papillary Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cediranib Ovarian Serous Surface Papillary Adenocarcinoma	National Cancer Institute (NCI)	P2	B (59)
Adavosertib Ovarian Serous Surface Papillary Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (52)
Olaparib Ovarian Serous Surface Papillary Adenocarcinoma	National Cancer Institute (NCI)	P1/2	CCC (48)